Free Trial
NYSE:PLX

Protalix BioTherapeutics (PLX) Stock Price, News & Analysis

Protalix BioTherapeutics logo
$1.54 +0.07 (+4.39%)
As of 01:47 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Protalix BioTherapeutics Stock (NYSE:PLX)

Key Stats

Today's Range
$1.50
$1.56
50-Day Range
$1.35
$1.60
52-Week Range
$0.82
$3.10
Volume
299,451 shs
Average Volume
849,272 shs
Market Capitalization
$122.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
Consensus Rating
Buy

Company Overview

Protalix BioTherapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
49th Percentile Overall Score

PLX MarketRank™: 

Protalix BioTherapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 565th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Protalix BioTherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Protalix BioTherapeutics has received no research coverage in the past 90 days.

  • Read more about Protalix BioTherapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Protalix BioTherapeutics are expected to grow by 3,000.00% in the coming year, from $0.01 to $0.31 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Protalix BioTherapeutics is -11.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Protalix BioTherapeutics is -11.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Protalix BioTherapeutics has a P/B Ratio of 3.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.18% of the outstanding shares of Protalix BioTherapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Protalix BioTherapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Protalix BioTherapeutics has recently increased by 1.83%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Protalix BioTherapeutics does not currently pay a dividend.

  • Dividend Growth

    Protalix BioTherapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.18% of the outstanding shares of Protalix BioTherapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Protalix BioTherapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Protalix BioTherapeutics has recently increased by 1.83%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Protalix BioTherapeutics has a news sentiment score of -0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Protalix BioTherapeutics this week, compared to 1 article on an average week.
  • Search Interest

    Only 5 people have searched for PLX on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Protalix BioTherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Protalix BioTherapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.50% of the stock of Protalix BioTherapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 16.53% of the stock of Protalix BioTherapeutics is held by institutions.

  • Read more about Protalix BioTherapeutics' insider trading history.
Receive PLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protalix BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

PLX Stock News Headlines

Protalix Lawsuit Dismissed After Bylaws Amendment
Washington Thinks They Own Your Bank Account
What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.
Protalix BioTherapeutics welcomes new finance chief
See More Headlines

PLX Stock Analysis - Frequently Asked Questions

Protalix BioTherapeutics' stock was trading at $1.88 at the beginning of the year. Since then, PLX stock has decreased by 17.4% and is now trading at $1.5530.

Protalix BioTherapeutics, Inc. (NYSE:PLX) released its earnings results on Friday, May, 9th. The company reported ($0.05) EPS for the quarter. Protalix BioTherapeutics had a negative net margin of 21.03% and a negative trailing twelve-month return on equity of 30.89%.

Shares of Protalix BioTherapeutics reverse split on Friday, December 20th 2019.The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Protalix BioTherapeutics' top institutional shareholders include Connor Clark & Lunn Investment Management Ltd. (0.62%), Orin Green Financial LLC (0.08%) and Harel Insurance Investments & Financial Services Ltd. (0.03%). Insiders that own company stock include Aharon Schwartz and Dror Bashan.
View institutional ownership trends
.

Shares of PLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Protalix BioTherapeutics investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Walmart (WMT) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
5/09/2025
Today
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:PLX
CIK
1006281
Employees
200
Year Founded
N/A

Price Target and Rating

High Price Target
$15.00
Low Price Target
$15.00
Potential Upside/Downside
+913.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.04
Trailing P/E Ratio
N/A
Forward P/E Ratio
148.00
P/E Growth
N/A
Net Income
$8.31 million
Net Margins
-21.03%
Pretax Margin
-21.00%
Return on Equity
-30.89%
Return on Assets
-11.74%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.98
Quick Ratio
1.27

Sales & Book Value

Annual Sales
$59.76 million
Price / Sales
1.97
Cash Flow
$0.08 per share
Price / Cash Flow
17.80
Book Value
$0.47 per share
Price / Book
3.15

Miscellaneous

Outstanding Shares
79,607,000
Free Float
68,995,000
Market Cap
$117.82 million
Optionable
Optionable
Beta
-0.21

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NYSE:PLX) was last updated on 8/7/2025 by MarketBeat.com Staff
From Our Partners